Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 31, Issue 5, 2007, Pages 1012-1022

  Ruhrmann, Stephan ^a   Kissling, Werner ^b   Lesch, Otto Michael ^c   Schmauss, Max ^d   Seemann, Ute ^b   Philipp, Michael ^e  

^a UNIVERSITY OF COLOGNE   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF VIENNA   (Austria)

^d Bezirkskrankenhaus Augsburg   (Germany)

^e Bezirkskrankenhaus Landshut   (Germany)

Author keywords

Cognitive symptoms; Depression; Flupentixol; Negative symptoms; Risperidone; Schizophrenia

Indexed keywords

BENZODIAZEPINE; BIPERIDEN; FLUPENTIXOL; RISPERIDONE;

ADULT; ADVERSE OUTCOME; AGED; AKATHISIA; ALBUMINURIA; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; EFFECT SIZE; EMOTIONAL DISORDER; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MOOD; NEGATIVE SYNDROME; PARKINSONISM; PATIENT COMPLIANCE; POST HOC ANALYSIS; PRESCRIPTION; PRINCIPAL COMPONENT ANALYSIS; RHINITIS; SCORING SYSTEM; SIDE EFFECT; TREMOR;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; DATA INTERPRETATION, STATISTICAL; DEPRESSIVE DISORDER; DYSKINESIA, DRUG-INDUCED; EMPLOYMENT; FEMALE; FLUPENTHIXOL; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 34249329193     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.02.014     Document Type: Article

References (75)

1. Bandelow B., Muller P., Frick U., Gaebel W., Linden M., Muller-Spahn F., et al. Depressive syndromes in schizophrenic patients under neuroleptic therapy. ANI Study Group Berlin, Dusseldorf, Gottingen, Munich, Federal Republic of Germany. Eur Arch Psychiatry Clin Neurosci 241 (1992) 291-295
2. Bell M.D., and Mishara A.L. Does negative symptom change relate to neurocognitive change in schizophrenia? Implications for targeted treatments. Schizophr Res 81 (2006) 17-27
3. Bell M.D., Lysaker P.H., Beam-Goulet J.L., Milstein R.M., and Lindenmayer J.P. Five-component model of schizophrenia: assessing the factorial invariance ofthe positive and negative syndrome scale. Psychiatry Res 52 (1994) 295-303
4. Bell M.D., Lysaker P.H., Milstein R.M., and Beam-Goulet J.L. Concurrent validity of the cognitive component of schizophrenia: relationship of PANSS scores to neuropsychological assessments. Psychiatry Res 54 (1994) 51-58
5. Bilder R.M., Goldman R.S., Volavka J., Czobor P., Hoptman M., Sheitman B., et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 159 (2002) 1018-1028
6. Carman J., Peuskens J., and Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Psychopharmacol 10 (1995) 207-213
7. Carpenter Jr. W.T. The treatment of negative symptoms: pharmacological and methodological issues. Br J Psychiatry Suppl (1996) 17-22
8. Chouinard G., Rosschouinard A., Annable L., and Jones B.D. Extrapyramidal symptom rating-scale. Can J Neurol Sci 7 (1980) 233-233.
9. Chouinard G., Jones B., Remington G., Bloom D., Addington D., MacEwan G.W., et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13 (1993) 25-40
10. Cohen J. Statistical power analysis for the behavioral sciences (1988), Lawrence Earlbaum, Hillsdale, NJ
11. Csernansky J.G., Mahmoud R., and Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346 (2002) 16-22
12. Davies A., Adena M.A., Keks N.A., Catts S.V., Lambert T., and Schweitzer I. Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety. Clin Ther 20 (1998) 58-71
13. Davis J.M., Chen N., and Glick I.D. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60 (2003) 553-564
14. Dollfus S., Olivier V., Chabot B., Deal C., and Perrin E. Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients. Schizophr Res 78 (2005) 157-159
15. Ehmann T.S., Khanbhai I., Macewan G.W., Smith G.N., Honer W.G., Flynn S., et al. Neuropsychological correlates of the PANSS cognitive factor. Psychopathology 37 (2004) 253-258
16. Ereshefsky L. Ein pharmakodynamisches und pathophysiologisches Modell der medikamentösen antipsychotischen Therapie in der Schizophrenie. In: Gerlach J. (Ed). Schizophrenie - Dopaminrezeptoren und Neuroleptika (1995), Springer, Heidelberg 149-184
17. Ereshefsky L. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. J Clin Psychiatry 60 Suppl 10 (1999) 20-30
18. Farde L., Nordstrom A.L., Wiesel F.A., Pauli S., Halldin C., and Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49 (1992) 538-544
19. Flaum M., and Andreasen N. The reliability of distinguishing primary versus secondary negative symptoms. Compr Psychiatry 36 (1995) 421-427
20. Gattaz W.F., Diehl A., Geuppert M.S., Hubrich P., Schmitt A., Linde I., et al. Olanzapine versus flupentixol in the treatment of inpatients with schizophrenia: a randomized double-blind trial. Pharmacopsychiatry 37 (2004) 279-285
21. Geddes J., Freemantle N., Harrison P., and Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321 (2000) 1371-1376
22. Gold J.M. Cognitive deficits as treatment targets in schizophrenia. Schizophr Res 72 (2004) 21-28
23. Good K.P., Rabinowitz J., Whitehorn D., Harvey P.D., DeSmedt G., and Kopala L.C. The relationship of neuropsychological test performance with the PANSS in antipsychotic naive, first-episode psychosis patients. Schizophr Res 68 (2004) 11-19
24. Goto M., Yoshimura R., Kakihara S., Shinkai K., Yamada Y., Kaji K., et al. Risperidone in the treatment of psychotic depression. Prog Neuropsychopharmacol Biol Psychiatry 30 (2006) 701-707
25. Green M.F., Marder S.R., Glynn S.M., McGurk S.R., Wirshing W.C., Wirshing D.A., et al. The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry 51 (2002) 972-978
26. Guy W. ECDEU assessment manual of psychopharmacology, revised (1976), National Institute of Mental Health, Rockville, MD
27. Harvey P.D., Green M.F., McGurk S.R., and Meltzer H.Y. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology (Berl) 169 (2003) 404-411
28. Hertling I., Philipp M., Dvorak A., Glaser T., Mast O., Beneke M., Ramskogler K., Saletu-Zyhlarz G., Walter H., and Lesch O.M. Flupenthixol versus risperidone: subjective quality of life as an important factor for compliance in chronic schizophrenic patients. Neuropsychobiology 47 (2003) 37-46
29. Hofer A., Baumgartner S., Bodner T., Edlinger M., Hummer M., Kemmler G., et al. Patient outcomes in schizophrenia II: the impact of cognition. Eur Psychiatry 20 (2005) 395-402
30. Hoyberg O.J., Fensbo C., Remvig J., Lingjaerde O., Sloth-Nielsen M., and Salvesen I. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand 88 (1993) 395-402
31. Hunter R.H., Joy C.B., Kennedy E., Gilbody S.M., and Song F. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev 2 (2003) CD000440.
32. Huttunen M.O., Piepponen T., Rantanen H., Larmo I., Nyholm R., and Raitasuo V. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial. Acta Psychiatr Scand 91 (1995) 271-277
33. Hyttel J., Larsen J.J., Christensen A.V., and Arnt J. Receptor-binding profiles of neuroleptics. Psychopharmacology Suppl 2 (1985) 9-18
34. Johnson D.A., and Malik N.A. A double-blind comparison of fluphenazine decanoate and flupentixol decanoate in the treatment of acute schizophrenia. Acta Psychiatr Scand 51 (1975) 257-267
35. Jones P.B., Barnes T.R., Davies L., Dunn G., Lloyd H., Hayhurst K.P., et al. Randomized controlled trial of the effect on quality of life of second- vs. first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63 (2006) 1079-1087
36. Kane J. Commentary: consensus statement on negative symptoms. Schizophr Bull 32 (2006) 223-224
37. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13 (1987) 261-276
38. Keefe R.S., Young C.A., Rock S.L., Purdon S.E., Gold J.M., and Breier A. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr Res 81 (2006) 1-15
39. Kirkpatrick B., Fenton W.S., Carpenter Jr. W.T., and Marder S.R. The NIMH-MATRICS Consensus Statement on Negative Symptoms. Schizophr Bull 32 (2006) 214-219
40. Kong D.S., and Yeo S.H. Flupentixol decanoate and fluphenazine decanoate in chronic schizophrenia. Singapore Med J 26 (1985) 551-555
41. Lancon C., Aghababian V., Llorca P.M., and Auquier P. Factorial structure of the Positive and Negative Syndrome Scale (PANSS): a forced five-dimensional factor analysis. Acta Psychiatr Scand 98 (1998) 369-376
42. Laughren T., and Levin R. Food and drug administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim. Schizophr Bull 32 (2006) 220-222
43. Laux G., Dietmaier O., and König W. Pharmakopsychiatrie (2000), Urban & Fischer, München, Jena
44. Leucht S. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 7 Suppl 1 (2004) S15-S20
45. Leucht S., Pitschel-Walz G., Abraham D., and Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 35 (1999) 51-68
46. Leucht S., Barnes T.R., Kissling W., Engel R.R., Correll C., and Kane J.M. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 160 (2003) 1209-1222
47. Leucht S., Wahlbeck K., Hamann J., and Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361 (2003) 1581-1589
48. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353 (2005) 1209-1223
49. Lindenmayer J.P., Kay S.R., and Opler L. Positive and negative subtypes in acute schizophrenia. Compr Psychiatry 25 (1984) 455-464
50. Lindenmayer J.P., Bernstein-Hyman R., Grochowski S., and Bark N. Psychopathology of schizophrenia: initial validation of a 5-factor model. Psychopathology 28 (1995) 22-31
51. Lindenmayer J.P., Grochowski S., and Hyman R.B. Five factor model of schizophrenia: replication across samples. Schizophr Res 14 (1995) 229-234
52. Lublin H., Eberhard J., and Levander S. Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. Int Clin Psychopharmacol 20 (2005) 183-198
53. Lykouras L., Oulis P., Psarros K., Daskalopoulou E., Botsis A., Christodoulou G.N., et al. Five-factor model of schizophrenic psychopathology: how valid is it?. Eur Arch Psychiatry Clin Neurosci 250 (2000) 93-100
54. Marder S.R., Davis J.M., and Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 58 (1997) 538-546
55. Meltzer H.Y., and McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25 (1999) 233-255
56. Möller H.J., van Praag H.M., Aufdembrinke B., Bailey P., Barnes T.R., Beck J., et al. Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia. Psychopharmacology (Berl) 115 (1994) 221-228
57. Montgomery S.A., and Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 134 (1979) 382-389
58. Müller M.J., Wetzel H., and Benkert O. Differential effects of high-dose amisulpride versus flupentixol on latent dimensions of depressive and negative symptomatology in acute schizophrenia: an evaluation using confirmatory factor analysis. Int Clin Psychopharmacol 17 (2002) 249-261
59. Myers J.E., and Thase M.E. Risperidone: review of its therapeutic utility in depression. Psychopharmacol Bull 35 (2001) 109-129
60. Opler L.A., Kay S.R., Rosado V., and Lindenmayer J.P. Positive and negative syndromes in chronic schizophrenic inpatients. J Nerv Ment Dis 172 (1984) 317-325
61. Pach J., Finkbeiner T., Glaser T., Haug J., Osterheider M., and Tegeler J. Positive and negative symptoms in chronic schizophrenic patients under maintenance therapy with flupentixol decanoate for a twelve month perioid. Fortschr Neurol Psychiatr 66 (1998) 442-449
62. Parent M., and Toussaint C. Flupentixol versus haloperidol in acute psychosis. Pharmatherapeutica 3 (1983) 354-364
63. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 166 (1995) 712-726 [discussion 727-33]
64. Peuskens J., Van Baelen B., De Smedt C., and Lemmens P. Effects of risperidone on affective symptoms in patients with schizophrenia. Int Clin Psychopharmacol 15 (2000) 343-349
65. Pinto R., Bannerjee A., and Ghosh N. A double-blind comparison of flupentixol decanoate and fluphenazine decanoate in the treatment of chronic schizophrenia. Acta Psychiatr Scand 60 (1979) 313-322
66. Racenstein J.M., Penn D., Harrow M., and Schleser R. Thought disorder and psychosocial functioning in schizophrenia: the concurrent and predictive relationships. J Nerv Ment Dis 187 (1999) 281-289
67. Remington G., and Kapur S. Atypical antipsychotics: are some more atypical than others?. Psychopharmacology (Berl) 148 (2000) 3-15
68. Rosenheck R., Perlick D., Bingham S., Liu-Mares W., Collins J., Warren S., et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 290 (2003) 2693-2702
69. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 47 (2002) 27-38
70. Serban G., Siegel S., and Gaffney M. Response of negative symptoms of schizophrenia to neuroleptic treatment. J Clin Psychiatry 53 (1992) 229-234
71. Tollefson G.D., and Sanger T.M. Negative symptoms: a path analytic approach to a double-blind, placebo-and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 154 (1997) 466-474
72. Wahlbeck K., Tuunainen A., Ahokas A., and Leucht S. Dropout rates in randomised antipsychotic drug trials. Psychopharmacology (Berl) 155 (2001) 230-233
73. Weiner D.M., Burstein E.S., Nash N., Croston G.E., Currier E.A., Vanover K.E., et al. 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther 299 (2001) 268-276
74. Wetzel H., Grunder G., Hillert A., Philipp M., Gattaz W.F., Sauer H., et al. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology-a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group. Psychopharmacology (Berl) 137 (1998) 223-232
75. Zachariah E., Kumari V., Galea A., Das M., Mehrotra R., Taylor D., Ruprah M., and Sharma T. Effects of oral procyclidine administration on cognitive functions in healthy subjects: implications for schizophrenia. J Clin Psychopharmacol 22 (2002) 224-226